Current Report Filing (8-k)
October 28 2021 - 4:31PM
Edgar (US Regulatory)
0001711754
false
0001711754
2021-10-27
2021-10-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 27, 2021
|
INMUNE
BIO INC.
|
|
|
(Exact
name of registrant as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State
or other jurisdiction
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
of
incorporation)
|
|
|
|
Identification
No.)
|
225 NE Mizner Blvd., Suite 640
Boca
Raton, Florida 33432
(Address
of Principal Executive Offices) (Zip Code)
(858)
964 3720
(Registrant’s
Telephone Number, Including Area Code)
Not
Applicable
(Former
Name or Former Address, If Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which
registered
|
Common
Stock, par value $0.001 per shares
|
|
INMB
|
|
The
NASDAQ Stock Market LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other
Events.
On
October 27, 2021, INmune Bio Inc., a Nevada corporation (the “Company”), issued a press release announcing multiple
poster presentations and a plenary talk at the upcoming 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, being
held in a hybrid format (in-person and virtual) from November 9-12 in Boston.
Details
of the presentations are as follows:
Late-breaking
oral presentation:
Title:
The Early Mild Alzheimer’s Cognitive Composite (EMACC): a meaningful primary cognitive endpoint in a phase 2 trial of XPro1595
in Alzheimer’s Disease (AD) with inflammation (ADi)
Presenter:
Dr. Judith Jaeger, Cognitionmetrics and Albert Einstein College of Medicine, Stamford, CT and Bronx, NY
Session:
LB12
Date:
Friday, November 12 (onsite)
Time:
9:55am ET
Late-breaking
oral communication:
Title:
Analyzing the CSF proteome to support decisions in an AD clinical trial program
Theme:
Clinical trials: biomarkers including plasma
Poster
(on-demand/virtual): LBR7
Date:
Tuesday, November 9
Time:
presentation will be available beginning at 8:00am ET
Poster
presentations:
Title:
Novel white matter imaging measures of neuroinflammation, axonal density and demyelination as potential biomarkers for trials in the
AD spectrum: validation in the largescale longitudinal multicenter ADNI studies
Theme:
Clinical trials: imaging
Poster
(onsite): LP3
Time:
all posters will be available beginning November 9 at 8:00am ET
Title:
MRI measures of white matter pathology can replace CSF sampling in AD clinical trials – case study from the XProTM a phase 1 trial
in Alzheimer’s patients with neuroinflammation
Theme:
Clinical trials: imaging
Poster
(onsite): LP4
Time:
all posters will be available beginning November 9 at 8:00am ET
Title:
Planning for Success: a Three-step process to Define Phase II Trial Size and Duration Using a Patient Enrichment Strategy using Phase
I Data and Public Databases
Theme:
Clinical trials: methodology
Poster
(onsite): LP11
Time:
all posters will be available beginning November 9 at 8:00am ET
A
copy of this press release is attached as Exhibit 99.1
Item
9.01 Financial statements and Exhibits
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INMUNE
BIO INC.
|
|
|
Date:
October 28, 2021
|
By:
|
/s/
David Moss
|
|
|
David
Moss
|
|
|
Chief
Financial Officer
|
3
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jun 2024 to Jul 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Jul 2023 to Jul 2024